Celgene
Celgene drops $710m drug, shares nosedive 7%
October 20, 2017Medical Communications, Research and Development Celgene, biotech, drugs, pharma, pharmaceutical
Celgene took a gamble when it spent $710 million up-front on an inflammatory disorder treatment, but it now looks likely …
Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership
August 11, 2017Medical Communications, Sales and Marketing Celgene, Sutro Biopharma, biotech, healthcare, life sciences, medicine, pharma, pharmaceutical
Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option …
NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment
August 4, 2017Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals
Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …
FDA approves Celgene and Agios’ acute myeloid leukaemia drug
August 2, 2017Research and Development, Sales and Marketing Celgene, FDA, Idhifa, acute myeloid leukaemia, agios, biotech, drugs, life sciences, medicines, pharma, pharmaceuticals
The FDA has given its approval for the commercialisation of Celgene and Agios Pharmaceutical’s Idhifa for the treatment of relapsed …
Celgene agrees one of the largest settlements for false claims on record
July 26, 2017Research and Development, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical, thalomid
It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the …
Celgene plays catch up with $1.4 billion immunotherapy deal
July 7, 2017Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1
Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …
New data shows pharma has not cut back on controversial payments to physicians
July 6, 2017Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant
Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …
New COO for Celgene
March 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene
Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. …
Celgene announces shock departure of COO
February 27, 2017Medical Communications, Sales and Marketing Celgene
Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. …
Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis
February 20, 2017Research and Development, Sales and Marketing Celgene, multiple sclerosis
Celgene’s drug to treat patients suffering with relapsing multiple sclerosis (RMS) was given a boost by positive Phase 3 trial …
Trump meets with top pharma execs, reiterates pledge to lower “astronomical” prices
January 31, 2017Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Eli Lilly, Novartis, PhRMA, Trump
President Trump convened with a number of top pharma execs at the White House on Tuesday to discuss the key …
Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU
January 27, 2017Sales and Marketing Celgene, Revlimid, multiple myeloma
Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …
Celgene to acquire Delinia in a potential $775 million deal
January 27, 2017Medical Communications Celgene, Delinia
Celgene has shelled out $300 million upfront, with a potential further $475 million in milestone payments, for Delinia, an autoimmune …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
NICE u-turns on Celgene’s drug for multiple myeloma
November 24, 2016Medical Communications Celgene, NICE, imnovid
NICE has performed a U-turn on Celgene’s Imnovid (pomalidomide) based on new data and the offer of a price reduction. …
Latest content
FibroFind appoints Lee Borthwick as CEO
